Uses of Asoct

Asoct is manufactured by GP Company - Pharm, S.A and registered by Lien Hop Pharmaceutical Co., Ltd., belongs to the group of anti-cancer drugs and affects the immune system. So what is the effect of Asoct and in what cases is it indicated?

Asoct medicine has the main ingredient containing the active ingredient Octreotide (in the form of Octreotid acetate) with a concentration of 0.1mg/ml, prepared in the form of an injection solution, packaged in a box of 5 ampoules, each with a capacity of 1ml. .

Asoct is indicated for use in the following cases:
Indicated in the relief of symptoms caused by tumors in the gastrointestinal endocrine system (GEP) including: ViPomas, Carcinoid tumors, alpha cell tumors pancreatic islets. Indicated for the treatment of patients with acromegaly when they cannot respond to radiotherapy, surgery, dopamine agonists, have received radiation therapy before but are waiting for results or do not want to undergo surgery. . Indicated in the prevention of complications after pancreatic surgery. Indicated for the treatment of severe diarrhea unresponsive to conventional therapy due to immunodeficiency (HIV/AIDS). Indicated for emergency treatment and prevention of early recurrent bleeding due to varices of the gastro-oesophageal varices in patients with cirrhosis, Asoct can be used in conjunction with endoscopic therapy.

3.1. How to use Asoct drug Asoct drug is prepared in the form of an injection solution, used for subcutaneous injection or intravenous injection, all procedures must be performed by a doctor, the patient is not allowed to use it without supervision. supervision of qualified medical staff. For Asoct when administered intravenously, usually 1 ampoule with a concentration of 0.5 mg is dissolved in 60 ml of physiological saline solution to achieve the recommended dose of 0.025 mg / hour. The diluted solution should be infused over a period of 20 hours with an infusion pump. The reconstituted solution is stable for 24 hours. 3.2. Dosage of Asoct For Acromegaly:
The recommended initial dose is 0.05 - 0.1 mg subcutaneously every 8 hours, depending on assessment of monthly GH levels and presenting symptoms. clinical status as well as the patient's ability to tolerate the drug to conduct dose adjustment. For most patients, the best daily dose is 0.2 to 0.3 mg. Do not exceed a maximum dose of 1.5mg/day. In combination with monitoring of plasma GH levels, the dose can be reduced after several months of treatment, if clinical symptoms do not show signs of improvement or GH levels do not decrease after a few months, treatment should be discontinued. For tumors of the endocrine system on the gastrointestinal tract - pancreas:
The initial dose should be 0.05mg, 1-2 times a day, injected subcutaneously, then gradually increase the dose to 0.2mg x 3 times a day depending on the patient's response and tolerability. Maintenance dose should be adjusted according to each case, may consider increasing the dose in some patients. For complications after pancreatic surgery:
Use at a dose of 0.1mg x 3 times a day, administered subcutaneously for 7 consecutive days, should start on the day before surgery and at least 1 hour before surgery. For bleeding due to esophageal varices due to cirrhosis:
Use at a dose of 0.025mg/hour by continuous intravenous infusion for a maximum of 5 days. Asoct can be diluted with physiological saline. For the elderly:
There are no reports or studies that show the need for a dose change or reduced tolerability in this population. Therefore, no dose adjustment is necessary in this subject. Not intended for use with children.

During the use of Asoct, besides the therapeutic effects of the drug, patients may experience the following undesirable effects:
Very common side effects such as: Abdominal pain, diarrhea, sadness vomiting, flatulence, headache, gallstones, hyperglycemia, pain at the injection site. Common side effects include: Constipation, vomiting, indigestion, abdominal distention, loose stools, fatty stools, discolored stools, dizziness, thyroid dysfunction, decreased thyroid function, bag sludge. cholecystitis, cholecystitis, hyperbilirubinemia, impaired glucose tolerance, hypoglycemia, asthenia, elevated liver enzymes, pruritus, rash, alopecia, dyspnea, bradycardia. Uncommon side effects such as dehydration, tachycardia. There are also side effects from spontaneous reports: Allergic reactions, hypersensitivity, anaphylaxis, subcutaneous urticaria, acute non-cholestatic hepatitis, acute pancreatitis, cholestatic hepatitis , cholestatic jaundice, cholestasis, jaundice, arrhythmia, gamma - glutamyl transferase, increased alkaline phosphatase. It is recommended that patients who experience any unusual signs during treatment with Asoct should immediately notify their doctor for timely adjustments.

When used concurrently with Asoct will reduce the gastrointestinal absorption of Cyclosporin and slow absorption of Cimetidine. The potency of Bromocriptin is increased when taken with Asoct. The effect of reducing the elimination of compounds metabolized by the cytochrome P450 enzyme system of Asoct cannot be excluded. Therefore, caution should be exercised when Asoct is co-administered with drugs that are weakly metabolised by CYP3A4, such as Digoxin, Carbamazepine, Terfenadin, Warfarin.

The use of Asoct is not indicated in the following subjects:
Patients with a history of hypersensitivity to Octreotide or any of the excipients contained in Asoct. Do not use Asoct in pregnant or lactating women. Do not give Asoct to young children. Asoct should be used with caution in the following cases:
When there are signs of tumor growth, it is necessary to choose another treatment method and monitor thyroid function in patients receiving long-term treatment with Asoct. During the use of Asoct, which can slow the heart rate, it is necessary to adjust the dose of drugs such as calcium channel blockers, beta blockers or electrolyte balancers and water control. Caution is advised as it may cause gallstones in some patients while being treated with Asoct. Asoct may reduce insulin requirements in patients with type 1 diabetes, type 2 diabetes or without diabetes because of the possibility of increased blood glucose during meals. Blood glucose should be closely monitored during treatment with Asoct because bleeding from esophageal varices may increase the risk of type I diabetes. Asoct may alter absorption. Fat absorption in some patients and vitamin B12 levels may be reduced. Therefore, vitamin B12 should be monitored in patients with a history of vitamin deficiency.

Store Asoct at a temperature below 30 degrees Celsius, keep the medicine in a cool, dry place, avoid direct exposure to sunlight or high temperature. Avoid misuse of drugs in young children, keep the medicine in a place with adult supervision. The shelf life of Asoct is 60 months from the date of manufacture. Do not use the medicine if the expiry date printed on the package has expired, the medicine appears discolored or cloudy in the solution. Above is all information about Asoct drug, patients need to carefully read the instructions for use, consult a doctor / pharmacist before using. Note, Asoct is a prescription drug, patients need to use it according to the doctor's prescription, absolutely do not self-treat at home.